Lates News

According to AI Fast News, Dongwu Securities released a research report on April 27, giving Yifeng Pharmacy (603939.SH) a "buy" rating. The main reasons for the rating include: 1) Business split: rapid growth in franchise and online business; 2) Store adjustments are coming to an end, and the company is optimistic about its expansion in 2026. (Daily Economic News)